Clinical trial

A Trial to Study Neladenoson Bialanate Over 20 Weeks in Patients With Chronic Heart Failure With Preserved Ejection Fraction

NCT03098979

Study summary

ClinicalTrials.gov

A Trial to Study Neladenoson Bialanate Over 20 Weeks in Patients With Chronic Heart Failure With Preserved Ejection Fraction

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE2

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

6 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Unmapped registry intervention Neladenoson bialanate (BAY1067197) Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Placebo Find medicine records · Find other trials using this name

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2017-05-10

PhasePHASE2

Conditions

Heart Failureverified · MONDO: heart failure

Interventions

Neladenoson bialanate (BAY1067197)DRUG

PlaceboDRUG

Sponsors & collaborators

Bayerlead sponsor

Mapped research locations

SofiaBulgaria3 MadridSpain2 ValenciaSpain2 ViennaAustria2 JerusalemIsrael2 LisbonPortugal2 TakatsukiOsaka, Japan2 ChicagoIllinois, United States1 St LouisMissouri, United States1 BarcelonaSpain1 BerlinGermany1 WarsawPoland1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03098979 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.